– Dr. Kieran Murphy presents the results of a clinical trial demonstrating the positive effect of protecting DNA from radiation exposure
TORONTO, May 29, 2023 /PRNewswire/ — Cora Therapeutics, a dynamic Toronto-based life sciences company, is proud to present the results of a clinical trial at the annual meeting of the Canadian Association of Interventional Radiologists ( CAIR) in Quebec City. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor and Chief Marketing Officer of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in protecting DNA from radiation exposure during imaging-guided aortic aneurysm stenting procedures. X-ray technology that saves lives.
During these high-intensity image-guided procedures, physicians were administered the antioxidant complex in two capsules one hour prior to exposure. The results clearly showed that the treated group experienced a significant 78% reduction in DNA breaks detected by P53 testing in their cell nucleus, exceeding expectations compared to the placebo group.
Dr. Murphy’s team has successfully demonstrated radiation protection of mitochondrial DNA in these subjects, marking an important milestone in the medical literature. The group given the antioxidant formulation showed a 54% decrease in mitochondrial DNA damage according to STAT 3 tests compared to the placebo group. Considering that mitochondrial DNA is maternally inherited and is 13 times more vulnerable to radiation than nuclear DNA, this achievement is very promising.
The rigorous DNA analysis was carried out by two independent teams of scientists, one at Princess Margaret Hospital, University Health Network, Toronto, and the other at McMaster University, Hamilton, Ontario, Canada. These institutions are recognized as Canada’s leading academic centers for health sciences. The research results, which represent a breakthrough in this field, will now undergo the peer-reviewed publication process. This antioxidant formulation has the potential to mitigate DNA breaks in patients undergoing CT scans, X-rays, mammograms, angiograms, and dental X-rays, and could become an integral part of the daily routine for the 2 million healthcare workers worldwide who perform X-ray-guided cardiac and angiographic interventions or work in radiology and cardiology departments.
Dr. Murphy’s earlier prospective randomized human study showed an impressive more than 90% reduction in DNA breaks among patients undergoing nuclear medicine bone scans. This pioneering research was published in the Journal of Vascular Interventional Radiology in 2016.
Classified as an oxidative stressor, radiation causes the buildup of harmful free radicals in the body, as do air pollution, ultraviolet light, smoking, processed diets, and frequent flights. Without protection, these harmful free radicals infiltrate DNA, raising the risk of DNA damage and genetic mutation. However, Halo Antioxidant Complex, which can be taken daily or one hour before radiation exposure, has shown significant efficacy in reducing DNA breaks, as indicated by collected data.
Halo is an antioxidant formulation consisting of carefully selected natural ingredients that meet NHPD guidelines, ensuring maximum safety and optimal efficacy while maintaining the highest standards for nutraceutical products. The proprietary blend of ingredients effectively neutralizes free radicals, preventing them from damaging body cells. Cora Therapeutics has employed pharmaceutical-grade scientific rigor to develop this innovative nutraceutical.
Halo has received clearance from Health Canada and the FDA. It is protected by four patents worldwide and has been the subject of nine peer-reviewed publications, cementing its scientific validity and potential.
About Cora Therapeutics:
Cora Therapeutics is at the forefront of data-driven healthcare solutions as an innovative company based in Toronto. Led by renowned interventional neuroradiologist, Dr. Kieran Murphy, the team of experts behind Halo is committed to minimizing collateral damage from radiation exposure. With more than 80 patents and more than 180 peer-reviewed publications, Dr. Murphy is a world leader in the field of interventional neuroradiology, practicing at the University Health Network of Toronto.
The team is complemented by esteemed scientific advisor, Mark Tarnopolsky, MD, Ph.D. FRCPC, pioneer in the evaluation and development of nutraceutical treatments for disorders associated with oxidative stress. These dedicated clinical scientists are supported by a strong team of health and wellness innovators with experience in bringing breakthrough products to market.
To learn more about Cora Therapeutics please visit www.coratherapeutics.com and for detailed information about Halo please visit www.haloantioxidant.com
CONTACT: Kieran Murphy, MD, kieran.murphy@uhn.ca
Logo – https://mma.prnewswire.com/media/2087072…
View original content: https://www.prnewswire.com/news-releases/el-doctor-kieran-murphy-presenta-los-resultados-de-un-ensayo-clinico-301836709.html
